Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been
considered promising therapeutic targets for cancer therapy. These cells have self-renewal …

Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

Background Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell
therapy has been shown to have activity in patients with relapsed or refractory multiple …

The clonogenic assay measures the capacity of single cells to form colonies in vitro. It is
widely used to identify and quantify self-renewing mammalian cells derived from in vitro …

Cancer stem cells (CSCs) have been identified as rare cell populations in many cancers,
including leukemia and solid tumors. Accumulating evidence has suggested that CSCs are …

Phenotypic and functional heterogeneity is one of the most relevant features of cancer cells
within different tumor types and is responsible for treatment failure. Cancer stem cells …

BACKGROUND. Treatment of B cell malignancies with adoptive transfer of T cells with a
CD19-specific chimeric antigen receptor (CAR) shows remarkable clinical efficacy …

Application of stem cell biology to breast cancer research has been limited by the lack of
simple methods for identification and isolation of normal and malignant stem cells. Utilizing …

PURPOSE A combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 chimeric
antigen receptor (CAR) T cells induced high response rates in patients with relapsed or …

Emerging evidence has suggested that the capability of a tumor to grow and propagate is
dependent on a small subset of cells within a tumor, termed cancer stem cells. Although data …